Effect of Intravenous Treatment of Silver Nanoparticles on Oocytes and Cells of their Follicular Environment under Conditions of Experimental Glomerulonephritis





female reproduction, functional state of the ovary, nanotechnology, nanomedicine


Nowadays, biomedical nanotechnology and nano medicine develops rapidly in the search for new drugs. Among them drugs based on silver nanoparticles (AgNPs) occupy the leading position. Studies that assess the effect of different doses and the multiplicity of the introduction of various sizes of AgNPs on reproduction of female animals gain topicality. Such studies will provide new data that will contribute to a fuller understanding of AgNPs mechanisms of action in the laboratory as well as provide a successful transition of silver nanotechnology into the clinics. Hence, the effect of AgNPs on mammalian cells and tissues requires further research.

The aim of the given study was to estimate the effect of intravenous treatment of silver nanoparticles on the functional state of the ovary in mice, namely oocytes (ovarian and meiotic maturation) and cells of their  follicular environment (number of live, with morphological signs of apoptotic and necrotic death), under conditions of experimental glomerulonephritis.

Experimental glomerulonephritis in mice was achieved by immunization of white laboratory mice of the first generation with a kidney antigen suspension derived from a parent. The treatment was carried out the following way: kidney antigen Suspension - intraperitoneal three times 1 time per day; the procedure was repeated in 3 weeks, one time intraperitoneally with the same dose (10 mkL of suspension per 10 grams of body weight of the animal). Silver nanoparticles (AgNPs, 30 nm) – intravenous three times: 1 time per day for 1 hour before immunization of animals with suspension of kidney antigen; as well as in 3 weeks once with the same dose (2 mg/kg).

Thus, the number of oocytes that resume meiosis in vitro from animals under experimental glomerulonephritis decreases comparing to the numbers in control animals; no inhibition of meiotic resumeption of oocytes of animals was established under conditions of AgNPs treatment; the AgNPs treatment under conditions of experimental glomerulonephritis increases the number of oocytes that resume meiosis in vitro compared with such values in the control and under conditions of experimental glomerulonephritis as well as the number of living cells increases and the number of cells with morphological signs of apoptotic death decreases in the follicular environment of oocytes.


1. Braun, G.; Friman, T.; Pang, H.; Pallaor, A.; de Mendoza, T.; Willmore, A.; Kotamraj, V.; Man, A.; She, Z.; Sugahar, K; Reich, N.; Teesalu, T.; Ruoslahti E. Etchable plasmonic nanoparticle probes to image and quantify cellular internalization. Nat. Mater. 2014, 13(9), рр 904–911. https://doi.org/10.1038/nmat3982
2. Malik, G.; Al-Harbi, A.; Al-Mohaya, S.; Al-Wakeel, J.; Al-Hozaim, W.; Kechrid, M.; Shetia, M.; Hammed D. Repeated pregnancies in patients with primary membranous glomerulonephritis. Nephron. 2002, 91(1), рр 21–24. https://doi.org/10.1159/000057600
3. Gilbert, S.; Weiner, D. National Kidney Foundation’s Primer on Kidney Diseases. Elselvier, 2014, 6th edition, 592.
4. Paltseva, E.M. Eksperimentalnyie modeli hronicheskih zabolevaniy pochek [Experimental models of chronic kidney disease]. Klinicheskaya nefrologiya 2009, 2, S. 37–42 (in Russian).
5. Kolomeets, N.Yu.; Averyanova, N. I.; Kosareva P. V. Razrabotka modeli hronicheskogo glomerulonefrita u belyih nelineynyih kryis [Development of a model of chronic glomerulonephritis in white non-linear rats] Sovremennyie problemyi nauki i obrazovaniya 2012, 3. URL: www.science-education.ru/103-6454 (in Russian).
6. Xue, Y.; Zhang, S.; Huang, Y.; Zhang, T.; Liu, X.; Hu, Y.; Zhang, Z.; Tang M. Acute toxic effects and gender-related biokinetics of silver nanoparticles following an intravenous injection in mice. J. Appl. Toxicol. 2012, 32, рр 890–899. https://doi.org/10.1002/jat.2742
7. Recordati, C.; De Maglie, M.; Bianchessi, S.; Argentiere, S.; Cella, C.; Mattiello, S.; Cubadda, F.; Aureli, F.; D’Amato, M.; Raggi, A.; Lenardi, C.; Milani, P.; Scanziani E. Tissue distribution and acute toxicity of silver after single intravenous administration in mice: nano-specific and size-dependent effects. Part Fibre Toxicol. 2015, 13, 12. https://doi.org/10.1186/s12989-016-0124-x
8. Reagan-Shaw, S.; Nihal, M.; Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22, рр 659–661. https://doi.org/10.1096/fj.07-9574lsf
9. Park, K.; Park, E.; Chun, I.; Choi, K.; Lee, S.; Yoon, J.; Lee B. Bioavailability and toxicokinetics of citrate-coated silver nanoparticles in rats. Аrch. Pharm. Res. 2011, 34, рр 153–158. https://doi.org/10.1007/s12272-011-0118-z
10. De Jong, W.; Van Der Ven, L.; Sleijffers, A.; Park, M.; Jansen, E.; Lovere, H.; Vandebriel, R. Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats. Biomaterials. 2013, 13(34), рр 8333–8343. https://doi.org/10.1016/j.biomaterials.2013.06.048
11. Tiedemann, D.; Taylor, U.; Rehbock, Ch.; Jakobi, J.; Klein, S.; Kues, W.; Barcikowski, S.; Rath D. Reprotoxicity of gold, silver, and gold-silver alloy nanoparticles on mammalian gametes. Analyst. 2014, 139(5), рр 931–942. https://doi.org/10.1039/c3an01463k
12. Lytvynenko, A.; Rieznichenko, L.; Sribna, V.; Stupchuk, M.; Grushka, N.; Shepel, A.; Voznesenska, T.; Blashkiv, T.; Kaleynykova, O. Functional status of reproductive system under treatment of silver nanoparticles in female mice. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2017, 6(5), рр 1713–1720. https://doi.org/10.18203/2320-1770.ijrcog20171930



How to Cite

Voznesenskaya, T., Stupchuk, M., Kaleinikova, O., Sribna, V., & Blashkiv, T. (2018). Effect of Intravenous Treatment of Silver Nanoparticles on Oocytes and Cells of their Follicular Environment under Conditions of Experimental Glomerulonephritis. Notes in Current Biology, (4(377), 92–99. https://doi.org/10.29038/2617-4723-2018-377-92-99